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Several clinical studies demonstrated that glucosamine sulfate (GS) is eﬀective in controlling osteoarthritis (OA), showing a
structure-modifying action. However, little is known about the molecular mechanism(s) by which GS exerts such action and
about the eﬀects of GS at a tissue level on osteoarthritic cartilage and other joint structures. Here we provide mechanistic evidence
suggesting that in vitro GS attenuates NF-κB activation at concentrations in the range of those observed after GS administration
to volunteers and patients, thus strengthening previous ﬁndings. Furthermore, we describe the eﬀects of GS at a tissue level on
the progression of the disease in a relevant model of spontaneous OA, the STR/ort mouse. In this model, the administration
of GS at human corresponding doses was associated with a signiﬁcant decrease of OA scores. Histomorphometry showed that
the lesion surface was also signiﬁcantly decreased, while the number of viable chondrocytes within the matrix was signiﬁcantly
increased. GS improved the course of OA in the STR/Ort mouse, by delaying cartilage breakdown as assessed histologically and
histomorphometrically.
1.Introduction
Glucosamine sulfate (GS) is used all over the world for the
therapy of osteoarthritis. Several clinical studies have shown
that it is eﬀective in controlling osteoarthritis (OA) not only
intermsofsymptoms,butalsoinreasonofitsabilitytodelay
theprogressionofthedisease,atleastasfarascanbeassessed
with the currently available clinical readouts [1–8]. However,
there is still considerable confusion and conﬂict as to the real
eﬀects of glucosamine as an osteoarthritis disease modifying
drug—in its heterogeneous preparations and diﬀerent salts.
Outcomes of the clinical trials have not been unanimous in
assigning eﬃcacy to glucosamine, due to a number of issues
[9, 10]. Nevertheless, GS is recommended in 6/10 existing
guidelines for the management of hip or knee OA [10].
Parallel to the clinical, a considerable amount of preclin-
ical, experimental pharmacology studies have been accruing
through the years, both by other groups and by ours, that
contribute to the understanding of the modes of action of
GS, although much certainly is yet to be done. Most of
the eﬀorts in this ﬁeld were accurately reviewed by Block
et al. [11]. It appears that the studies on glucosamine
were mainly performed along two lines of research, one
that employed mostly in vitro and cell biology methods,
aimed at shedding light on the molecular mechanism, or
mechanisms, through which glucosamine exerts its actions
and the other, aimed at a thorough elucidation of the eﬀects
of GS, or other salt preparations, at a tissue level using in
vivo approaches. Again, the diﬀerences in glucosamine salts
used,ininvitroconcentrationsaswellasinanimalprotocols,
have sometimes led to confusing results. In the present study
we have tried to contribute to clariﬁcation of such issues by
applying what we believe are the most appropriate in vitro
and in vivo protocols using standardized in vitro culture
systems, a well-characterized animal model of OA pathology,
a therapeutically relevant preparation and concentrations of
GlcN salts, and standardized outcome measures, as pointed
out by Block and colleagues [11].
Among the major factors hindering the interpretation
of the results obtained with glucosamine across cell culture2 International Journal of Rheumatology
studies are the diﬀerent concentrations used and the amount
of glucose contained in the culture medium that could com-
pete with glucosamine uptake. Here, we studied the eﬀects
of GS on the expression of several inﬂammation and matrix
degradation factors, as assessed by quantitative real-time
PCR on a relevant chondrocyte model, at concentrations
found in plasma of human subjects after oral administration
[12,13]andinamediumcontainingphysiologicalmonosac-
charide concentrations (5mM) and in which galactose
substitutes for glucose, thus facilitating glucosamine uptake
in chondrocytes.
On the other hand, animal studies with glucosamine
are also performed using diﬀerent salts, doses, and animal
species, and employing surgical induction of OA, while
human OA is mostly spontaneous, idiopathic, and age-
related. STR/ort mice spontaneously develop genuine OA
with age; the whole joint undergoes degenerative changes
very much like human OA, that consist in articular cartilage
peeling, clefting, ﬁbrillation, erosion; subchondral bone
sclerosis with osteocyte necrosis; focally, fatty involution of
the epiphyseal bone marrow; synovial hyperplasia; chondro-
osseous metaplasias in capsula, ligaments, periosteum, lead-
ing to chondrophyte and osteophyte formation with ectopic
bone development [14] and own data. Besides, STR/ort
mice display obesity, hyperlipidemia, and hyperinsulinemia
[15–17] ,a l lf e a t u r e st h a tc o n s t i t u t er i s kf a c t o r sf o rO Af o r
humans. For all these observations, the clinical picture of the
STR/ort mice closely resembles that of a typical human OA
patient, so far as is known about either. Here we assessed the
eﬀects of GS on the course of OA in this mouse strain at a
tissue level.
2.MaterialsandMethods
2.1. Materials. Crystalline glucosamine sulfate (GS) used
is from Rottapharm (Monza, Italy). Leibovitz’s Medium
(containing5mMgalactose),Dulbecco’sphosphate-buﬀered
saline (PBS), and Trypsin/EDTA were purchased from
Invitrogen (CA, USA). Recombinant human Interleukin-1β
(IL-1β, 100.000U/mL, 2μg/mL) was purchased from Roche
(IN, USA). U0126 was purchased from Cell Signaling (MA,
USA) and SB242235 from Sigma (MI, USA).
2.2.CellCulture. SW1353cells(humanchondrosarcomacell
line from ATCC, Promochem, UK) were grown adherent
in Leibovitz’s medium supplemented with 10% FBS and
gentamicin(50μg/mL),at37◦C without Co2.C o n ﬂ ue n tc ells
were synchronized by incubating with Leibovitz’s 0,4% FBS
for 16h. Cells were then pretreated for 1h with GS 0,1–
100μM for expression analysis of inﬂammatory and matrix
degradative markers, and with GS 0,001–100μMf o re x p r e s -
sion analysis of transcription factors subunits. The pre-
treatmentwasfollowedbystimulationwithIL-1β2ng/mLor
IL-1β 10ng/mL for expression analysis of inﬂammatory and
matrixdegradativemarkersortranscriptionfactorssubunits,
respectively. Stimulation treatment with IL-1β lasted for 1, 2,
6, or 24h depending from each gene kinetics of induction.
Pretreatment and stimulation were performed in Leibovitz’s
0,4% FBS.
2.3. Total RNA Puriﬁcation. Total RNA was puriﬁed using
ABI PrismTM 6100 Nucleic Acid PrepStation, an RNA
isolation platform from Applied Biosystems (Foster City,
CA). This method uses a vacuum system that allows a
reproducible puriﬁcation without contaminations. Puriﬁed
RNA was stored at −80◦C.
2.4. Reverse Transcription (RT). Total RNA was retro-
transcribed with the High-Capacity cDNA Archive Kit
(Applied Biosystems), adding 50μLo ft o t a lR N At o5 0μLo f
reactionmix.Thereaction(ﬁnalvolume:100μL)wascarried
out in a BioRad (Hercules, CA) “iCycler.”
Quantitative PCR (Real-Time PCR): Real-Time PCR is
based on the quantitative relationship between the starting
amount of the target sequence and the quantity of the PCR
product obtained at each reaction cycle. Speciﬁc human and
rat probes and primers used were purchased from Applied
Biosystems as TaqMan Gene Expression Assays, while the
h u m a np r o b ea n dp r i m e r so ft h ee n d o g e n o u sc o n t r o l
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) were
PDARs (Pre-Developed TaqMan Assay Reagents). The reac-
tion was performed using the ABI PRISM 7000 Sequence
DetectionSystem.Dataanalysis,normalizedaccordingtothe
ampliﬁed values of GAPDH, was done with the aid of the
Relative Quantiﬁcation/RQ Software (Applied Biosystems).
Each sample was analyzed in triplicate.
2.5. Statistical Analysis. For each experiment, percentage
eﬀect of GS on gene expression induced by IL-1β was
calculated starting from the relative quantity data obtained
with the Relative Quantiﬁcation/RQ Software (Applied
Biosystems).
2.6. Animal Studies. For our purposes, Harlan Italy devel-
oped a breeding colony of STR/ort mice. In order to
double-check that the phenotype was still consistent with
what described [14], we analyzed histologically mice from
diﬀer entgr oupsofage:4,5,6,7,8,and9monthsold,n=20–
24 (data not shown). In our hands, 100% of 5-month-old
male STR/ort mice presented some degree of OA. Therefore,
as we aimed for a curative protocol, and not a preventive
one, we decided to enroll mice in each study as they reached
5 months of age (n = 20–22). One group of 5-month old
mice was used as a “baseline” control. Glucosamine sulfate
(Rottapharm) was administered subcutaneously dissolved
in saline at the doses of 200 and 400mg/kg. Mice were
randomized for treatment, treated once daily for 3 months,
and euthanized at the end of the treatment with collection of
tissue (both hind limbs) for histology. Several nonconsecu-
tive sections from each knee were stained with toluidine blue
and blind scored according to both Mankin’s and the OARSI
method. Histomorphometry was also performed using the
Osteomeasure image analysis system (Osteometrics, Atlanta,
GA), with the operator still blinded to the experimental
groups. Histomorphometric parameters analyzed were (i)
lesion surface and (ii) number of viable chondrocytes
within the articular cartilage. All scoring and measurements
were performed on the medial tibial compartment of the
knees. Statistical analysis was ANOVA followed by Dunn’sInternational Journal of Rheumatology 3
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Figure 1: Eﬀe c to fG So nI L - 1 β-induced gene expression of IL-1β (a), COX-2 (b), IL-6 (c), and TNFα (d). One hour after the pretreatment
with GS (0,1–100μM), SW1353 are stimulated with IL-1β (2ng/mL) as indicated. Representative pictures of 3 to 5 independent experiments
are shown. Data are mean ± SD of three replicates.
or Dunnett’s tests comparing all treatment groups versus
vehicle.
3. Results
3.1. Cell Studies. As isolated primary chondrocytes have
little proliferation capacity and tend to dediﬀerentiate to
ﬁbroblast-like cells in culture, we used a human chondrosar-
coma cell line (SW1353) as a well-established chondrocyte
model. We started performing time course experiments
to determine the optimal IL-1β stimulation time for each
parameter analyzed (data not shown). The experiments have
been performed three times with comparable results. In
this paper, we show representative experiments done at the
optimal stimulation time for each transcript.
3.1.1. GS Eﬀect on Inﬂammatory Markers. We analyzed
some inﬂammatory markers commonly involved in the OA
disease.IL-1β induced the expression of all the inﬂammatory
marker analyzed. The study of COX-2 was done after 6h
of stimulation, and in these conditions GS was eﬀective in
reducing its expression with a minimal eﬀective concen-
tration (MEC) of 1μM. The other inﬂammatory markers
considered in our study are cytokines. The local production
of cytokines is strongly induced in the articular joint of OA
patients. We analyzed the gene expression of IL-1β and IL-
6 after 6h of stimulation with IL-1β, while the transcript
levels of TNFα were studied after 1h of stimulation. The
MECvaluesforGSonalltheinﬂammatorymarkersanalyzed
ranged between 1 and 10μM( Figure 1).
3.1.2. GS Eﬀect on Matrix Degradative Markers. We analyzed
two extracellular matrix degradative markers commonly
involved in the OA disease: a matrix metalloproteinase
MMP-3 (stromelysin-1) and ADAM-TS5 (a disintegrin and
metalloproteinase with thrombospondin motifs) also called
aggrecanase 2. The analysis has been performed after 6h of
treatments for MMP-3 and after 24h for ADAM-TS5. The4 International Journal of Rheumatology
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Figure 2: Eﬀect of GS on IL-1β-induced gene expression of MMP-3 (a) and ADAM-TS5 (b). One hour after the pretreatment with GS (0,1–
100μM), SW1353 are stimulated with IL-1β (2ng/mL) as indicated. Representative pictures of 3 to 5 independent experiments are shown.
Data are mean ± SD of three replicates.
MEC values for GS on matrix degradative markers analyzed
ranged between 0.1 and 1μM( Figure 2).
3.1.3. GS Eﬀect on NF-κB and AP-1 Subunits. The gene
expression analysis of NF-κB subunits (p50, p52, and RelB)
and of JunB was performed after 2h of IL-1β stimulation.
T h eM E Cv a l u e sf o rG So nt r a n s c r i p t i o nf a c t o r so ft h eN F -
κB family members ranged between 1nM and 0.1μM. JunB
MEC value for GS was 1nM (Figure 3).
3.2. In Vivo Results. Eight-month-old STR/ort mice show a
histological picture resembling that of human OA with a
constant progression with age; the whole joint undergoes
degenerative changes very much like human OA, that
consist in articular cartilage peeling, clefting, ﬁbrillation,
erosion; subchondral bone sclerosis with osteocyte necrosis;
focally, fatty involution of the epiphyseal bone marrow;
synovial hyperplasia; and chondro-osseous metaplasias in
capsula,ligaments,periosteum,leadingtochondrophyteand
osteophyte formation with ectopic bone development as
depicted in Figure 4 (a).
In this relevant animal model of spontaneous OA, we
observed that all OA scores were signiﬁcantly decreased fol-
lowing treatment with GS compared to vehicle (Figure 4(b),
Figure 5(a) and data not shown). In particular, the OARSI
score takes into account both the depth of the lesion on the
articular surface, and its width. We observed that both doses
of GS substantially and signiﬁcantly improved the OARSI
score. A histomorphometrical analysis was also performed.
We observed that all parameters tended to an improvement
following treatment with GS; in particular, the lesion
surface on the articular surface was signiﬁcantly decreased
(Figure 5(b)) and the number of live chondrocytes within
the articular cartilage matrix (viable cells/total cartilage
volume) signiﬁcantly increased (Figure 5(c))i nb o t hG S
groups compared to vehicle.
4. Discussion
4.1. Findings in Cell Biology. The mechanism of action
beneath the favorable actions of GS has not yet been fully
elucidated; however, evidence is available that deserves to be
discussed. To understand the molecular site(s) of action of
glucosamine, several in vitro studies have been performed
demonstrating diﬀerent relevant activities using concentra-
tions in the range of 1μM–1mM. Largo and coworkers [18]
indeed demonstrated that GS can inhibit NF-κBa c t i v i t ya s
well as the nuclear translocation of p50 and p65 proteins
in cultures of human osteoarthritic chondrocytes stimulated
with IL-1β. These observations allow us to postulate the
involvementofNF-κBinGS’smechanismofaction,although
GS was used in a concentration range between 0.2 and
2mM, much higher than that found in the plasma by
Persiani et al. after GS administration [12]. A very recent
paper demonstrated that, at least in rabbits, plasma levels
of glucosamine appeared to be well correlated with cartilage
concentrations, being, therefore, useful to predict the target
cartilageconcentrationanditspharmacologicalactivity[19].
Ontheotherhand,Chanetal.[20]showedthatglucosamine
at these clinically relevant concentrations (about 20μM)
reduced COX-2, iNOS, and mPGEs1 gene expression and
PGE2 synthesis after IL-1β stimulation, suggesting that also
in this range of concentration Glucosamine can control
the cascade triggered by inﬂammatory stimuli. Of late,
observationshavebeenpublishedthatpointouttheblunting
eﬀectofGlucosamineonNF-κB-dependenttranscriptionvia
an epigenetic mechanism [21].
IL-1β is a potent proinﬂammatory cytokine produced in
high amounts in the OA joint [22, 23], where it induces a
series of gene expression alterations. This cytokine triggers
theexpressionofinﬂammatoryfactorssuchasCOX-2,iNOS,
IL-6, IL-1β,T N F α, and matrix degradation factors, namely,
MMPs and ADAM-TSs. Most of these genes are underInternational Journal of Rheumatology 5
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Figure 3: Eﬀe c to fG So nI L - 1 β-induced gene expression of NF-κB1/p50 (a), NF-κB2/p52 (b), RelB (c), and JunB (d). One hour after the
pre-treatment with GS (0,001–100μM), SW1353 are stimulated with IL-1β (10ng/mL) for 2h. Representative pictures of 3 to 5 independent
experiments are shown. Data are mean ± SD of three replicates.
transcriptional control of the nuclear factor κB( N F - κB).
NF-κB is a collective name for homo- and hetero-dimeric
complexes of Rel family polypeptides, which are present,
in mammals, with ﬁve members: RelA (p65), RelB, c-Rel,
NF-κB1/p50, and NF-κB2/p52. In unstimulated cells, the
majority of NF-κB dimers are retained in the cytoplasm
as an inactive complex bound to inhibitor proteins (IκBs).
In response to diﬀerent activating stimuli, including IL-1β,
IκBs are degraded proteolitically by the 26S proteasome,
after phosphorylation by IKK and polyubiquitination. NF-
κB dimers then translocate to the nucleus and bind to
speciﬁc consensus sequences (κB elements) along the DNA,
promoting gene transcription. To clarify the mode of action
of GS at therapeutically achievable concentrations we chose
an appropriate human chondrocyte model, the human
chondrosarcoma cell line SW1353 [24–26]. Moreover, as
well depicted by Block et al. [11], glucose concentration in
the medium is one of the major confounding factors for
the interpretation of in vitro experiment results reported
in the literature. It is known that most of the published
in vitro studies with glucosamine have been performed
in culture medium containing 25mM of glucose, that
could easily compete with glucosamine for the ubiquitous
sodium-independent facilitative glucose transporter GLUT1
impeding eﬃcient glucosamine uptake into cells. Therefore,
our experiments in SW1353 cells were performed in Lei-
bovitz medium containing 5mM D-galactose a less eﬃcient
substrate for GLUT-1 [27] instead of D-glucose. Under these
physiologically relevant conditions, we employed quanti-
tative RT-PCR to study GS’s activity in counteracting the
eﬀects of IL-1β on the expression of several genes relevant
for inﬂammation and matrix metabolism. We demonstrated
that GS sulfate is eﬀective in a dose-dependent manner on
modulating OA-relevant gene expression triggered by IL-1β,
also at the low concentrations (1–10μM) found in human
pharmacokinetic studies. These events are probably initiated
by a decrease in NF-κB translocation. Indeed, Letari et al.
[28] showed by EMSA that the increase in nuclear NF-κB6 International Journal of Rheumatology
(a)
(b)
Figure 4: Representative histology images of articular cartilage
from 8-month-old STR/ort mice that were treated with GS
200mg/kg (b) or vehicle (a) for 3 months.
triggered by IL-1β was blunted by GS, and the eﬀect on
transcription might be sustained thereafter by the inhibition
of NF-κB subunit expression. Of note, these observations are
in agreement with the studies discussed above [18, 20, 21,
29].
4.2.HistopathologicalandFurtherInVivoOutcomes. We have
tried to provide some contribution to a better understanding
of the eﬀect of GS at a tissue level. In the search for reliable
andpredictiveanimalmodelsofOAtousefordrugdiscovery
purposes, we considered that surgical OA in the animal may
not necessarily reﬂect all aspects of spontaneous idiopathic
OA in the elderly; therefore, we resolved to also take advan-
tage of a mouse strain that is believed to be a relevant model
of human OA, the STR/ort mouse (reviewed by Mason et
al. [14]). The pathological features of this particular mouse
strikingly recapitulate several characteristics of human OA
patients. In this model, we observed that GS improved the
pathological severity and the histological parameters of OA.
These observations are consistent with the clinical eﬀect of
GS.
Current methods employed in the clinics to assess
eﬃcacy of compounds aimed at modifying the course of
OA do not allow for a detailed investigation of the eﬀects
of such compounds at a tissue level. To this end, the use
of animal models of OA has represented a very important
andenlighteninginstrument,andindeeddiscussionhasbeen
going on for long on what models are most representative
of human OA, and predictive. Surgical models employing
various rodent and nonrodent species are deﬁnitely the most
studied and used so far.
An early study with GS was that of Altman and Cheung
[30]. Partial meniscectomy was performed to adult rabbits
thatwerethentreatedwithGS100or200mg/kg /die orvehi-
cle for 12 weeks. Histology showed that rabbits treated with
vehiclesuﬀeredsevereﬁbrillationandcleftingofthearticular
cartilage accompanied by chondrocyte loss at the operated
knee; treatmentwith GS signiﬁcantlyprevented those degen-
erative changes to a remarkable extent. Expression of various
MMPs was also investigated by immunostaining and found
increased in the vehicle but not in the GS groups.
A limit of that study was that of a preventive treatment,
that is, knowing when the injury occurred, treatment was
started immediately. That situation does not necessarily
mimic the human condition, where disease develops spon-
taneously and progressively and starts to be treated when
already advanced to some degree.
The same criticism may not apply to another study,
that of Tiraloche et al. [31]i nw h i c had i ﬀerent surgical
protocol in rabbits was applied, transection of the anterior
cruciate ligament (ACLT), and in which treatment with Glu-
cosamine hydrochloride (100mg/die) was started 3 weeks
after surgery. The histopathological features observed were
parallel to those reported above. In this study, Glucosamine
hydrochloride failed to produce a signiﬁcant improvement
in most of the OA parameters evaluated, except one, that is,
GAG loss. However, it must be considered that Glucosamine
hydrochloride has poorer pharmacokinetics than GS [12, 13,
32, 33].
A very recent work yet again demonstrated eﬃcacy of
GS in a diﬀerent animal model, in which a true curative
protocol was employed [29]. These authors performed ACLT
in adult rats, and then allowed OA to develop for ﬁve weeks
before starting treatment. The authors then provided an
impressive array of readouts, that included assessment of
nociception (mechanical allodynia, weight bearing distribu-
tion test) and macroscopic and histopathologic evaluations
of tissue degeneration. In all of these measurements, GS
(250mg/kg/die) had a signiﬁcant eﬀect in reducing the
severity of OA, both in terms of pain and of structural
integrity of the tissues involved. Furthermore, the authors
have also provided hints to a possible cellular signaling
pathway involved in the molecular action(s) of GS. They
observedthatbothp38MAPKandJNK,twokeyintracellular
mediators of inﬂammatory signals, were activated following
OA establishment, and that treatment with GS hampered
these activations. Such observations are in agreement with
evidence coming from cell culture experiments, which are
discussed above.
4.3. Conclusion. Evidence concerning GS’s mechanism of
action has been shedding some light on how GS exerts its
eﬀects. It appears now from several studies, including ours,
that GS inhibits gene expression of diﬀerent inﬂammation
and matrix degradation markers, at concentrations similar
or even lower than that found in human plasma after oral
therapeutic doses, by interfering with the NF-κBp a t h w a y .I t
is deﬁnitely likely that there is more than that as to what GS
doeswithinthecell,andthatmuchremainstobeestablished.
At the same time, to the best of our knowledge this is the ﬁrstInternational Journal of Rheumatology 7
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Figure 5: (a) Eﬀect of subcutaneous administration of GS on OARSI score in STR/ort mice. Data are represented as median. (b) Eﬀect
of subcutaneous administration of GS on Lesion surface/total surface in STR/ort mice. Data are represented as mean ± SE. (c) Eﬀect of
subcutaneous administration of GS on n. of viable cells/total cartilage volume in STR/ort mice. Data are represented as mean ± SE. ∗ =
P<0.05 versus vehicle (ANOVA). The vehicle group is always statistically diﬀerent from the na¨ ıve 5-month-old group.
study that describes in detail the eﬀects of GS at a tissue level
in improving articular cartilage health in a spontaneously
occurring OA model that recapitulates so many aspects of
human idiopathic OA in the elderly.
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